Table II.
Effects of post-diagnostic aspirin use on fatal and lethal (development of metastases to bone, other organs, or fatal) prostate cancer
| Fatal prostate cancer (n=177 events)
|
Lethal disease (n=265 events)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Aspirin Use | RR | 95% CI | RR | 95% CI | RR | 95% CI | RR | 95% CI |
| Quantity, updated since diagnosis | ||||||||
| Non-user | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| < 2 tabs/week | 0.73 | 0.42, 1.26 | 0.93 | 0.52, 1.67 | 0.91 | 0.60, 1.36 | 1.12 | 0.72, 1.72 |
| 2 -5 tabs/week | 0.94 | 0.49, 1.78 | 1.08 | 0.55, 2.14 | 0.93 | 0.55, 1.56 | 1.05 | 0.62, 1.80 |
| ≥ 6 tabs/week | 0.99 | 0.67, 1.45 | 1.16 | 0.74, 1.82 | 0.94 | 0.68, 1.30 | 1.08 | 0.76, 1.54 |
| test-for-trend (p-value) | 0.63 | 0.99 | ||||||
| Quantity at baseline/diagnosis | ||||||||
| Non-user | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| < 2 tabs/week | 1.11 | 0.71, 1.73 | 1.39 | 0.85, 2.28 | 1.17 | 0.81, 1.68 | 1.37 | 0.92, 2.03 |
| 2 -5 tabs/week | 0.84 | 0.49, 1.42 | 1.08 | 0.61, 1.91 | 0.96 | 0.63, 1.45 | 1.20 | 0.78, 1.84 |
| ≥ 6 tabs/week | 0.92 | 0.62, 1.37 | 1.19 | 0.76, 1.87 | 0.91 | 0.65, 1.27 | 1.14 | 0.79, 1.64 |
| test-for-trend (p-value) | 0.62 | 0.70 | ||||||
| Frequency, updated since diagnosis | ||||||||
| < 2 days/week | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 2 -3 days/week | 0.76 | 0.38, 1.52 | 0.92 | 0.44, 1.91 | 0.65 | 0.36, 1.19 | 0.72 | 0.39, 1.33 |
| 4 -5 days/week | 0.66 | 0.24, 1.87 | 0.67 | 0.23, 1.97 | 0.99 | 0.50, 1.99 | 1.07 | 0.52, 2.19 |
| 6 -7 days/week | 0.93 | 0.65, 1.32 | 1.14 | 0.76, 1.71 | 0.95 | 0.71, 1.26 | 1.13 | 0.82, 1.55 |
| test-for-trend (p-value) | 0.42 | 0.35 | ||||||
| Frequency at baseline/diagnosis | ||||||||
| < 2 days/week | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
| 2 -3 days/week | 0.84 | 0.39, 1.81 | 0.96 | 0.43, 2.14 | 0.90 | 0.48, 1.67 | 1.02 | 0.54, 1.93 |
| 4 -5 days/week | 1.08 | 0.51, 2.30 | 1.03 | 0.45, 2.36 | 1.17 | 0.63, 2.15 | 1.19 | 0.63, 2.26 |
| 6 -7 days/week | 1.00 | 0.71, 1.39 | 1.33 | 0.90, 1.97 | 1.01 | 0.76, 1.33 | 1.26 | 0.92, 1.73 |
| test-for-trend (p-value) | 0.19 | 0.18 | ||||||
adjusted for age (months), period (2-year intervals), family history (yes/no), race (Asian, Caucasian or African-American), height (<66, 66-67.9, 68-69.9, 70-71.9, 72+ inches), BMI at dx (<21, 21-22.9, 23-24.9, 25-27.4, 27.5-29.9, 30+ kg/m2), tomato sauce (<0.25, 0.25-1, 1-2, 2+/wk), vigorous physical activity (quintiles, hours), smoking (never or curr or quit < 10 yrs & < 15 cigs/day), quit>10 yrs, vitamin D (quintiles,), fish (<2/mo, 2/mo-1/wk, >1-3/wk, 3+/wk), red meat (quintiles), cholesterol-lowering drugs (non-user, current user), total kcal (quintiles), gleason score (4-6, 7, 8-10), aspirin use prior to diagnosis (tabs/wk), TNM stage (T1/T2 and N0/M) vs. T3/T4 or N1 or M1) and initial treatment (WW, RP, RT, HT, other, missing)
first post-diagnostic measurement
Non-users are defined as those taking aspirin< 2 days/week in a given cycle